Evaluating the Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Patients With Type 2 Diabetes: a Multi-center, Randomized, Parallel Controlled Clinical Trial With an Extension Phase

Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study

Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.

Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.